11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

Schaeffers Research • Oct 12, 2026

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.

Business Wire • Oct 6, 2026

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.

MarketBeat • Oct 3, 2026

10 Stocks With Massive Short Squeeze Potential

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?

Schaeffers Research • Oct 1, 2026

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum.

Business Wire • Sep 23, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference.

Business Wire • Sep 8, 2026

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.

The Motley Fool • Sep 1, 2026

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

Market Watch • Aug 27, 2026

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.

The Motley Fool • Aug 21, 2026